WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million. Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback